The retinoic acid analog CBS-211A potentiates the 1 alpha,25-dihydroxyvitamin D3-induced differentiation of U937 cells

  • Agents Actions. 1993 Jan;38(1-2):91-9. doi: 10.1007/BF02027219.
M Taimi  1 ,  H Defacque ,  T Commes ,  J Favero ,  J Dornand ,  J Marti
Affiliations
  • 1. INSERM U65, Département de Biologie-Santé, Université de Montpellier II, France.
PMID: 8480542 DOI: 10.1007/BF02027219
Abstract

We report the effect of CBS-211A, a synthetic retinoid analog, designed for topical eye administration, on the growth and differentiation of myelomonocytic cells. This compound was assayed alone or in combination with 1 alpha,25-dihydroxyvitamin D3 (1 alpha,25(OH)2D3), since we previously evidenced a synergism of retinoic acid (RA) and 1 alpha,25(OH)2D3 in the induction of U937 cell differentiation. Unlike RA, CBS-211A neither affected the growth of myelomonocytic cells nor differentiated them. Nevertheless, when it was associated with 1 alpha,25(OH)2D3, CBS-211A strongly potentiated the 1 alpha,25(OH)2D3-induced inhibition of U937 cell proliferation and caused a dramatic increase in their differentiation toward monocytes/macrophages. The co-inducing effect of CBS-211A was restricted to U937 cells. Our data suggest that CBS-211A may have therapeutic implications in the treatment of certain kinds of myelomonocytic leukemia. CBS-211A also provides an interesting tool to understand the mechanisms involved in the differentiation of myelomonocytic cells.

Products